SEC Filing Analysis: Adaptive Biotechnologies Corp

Executive Summary

• Trading Significance: Low
• Key Takeaway: An officer at Adaptive Biotechnologies has filed a notice of a proposed sale of 10,000 shares, valued at approximately $147,100, under a pre-arranged 10b5-1 trading plan.
• Market Impact: Minimal market impact is expected due to the small transaction size and its pre-planned nature.

Company Information

Field	Value
Company	Adaptive Biotechnologies Corp
Ticker Symbol	Not provided in filing
CIK	0001478320
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Harlan Robins
CIK	0001780851
Title/Position	Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-10 (Approximate)
Transaction Code	Not Applicable
Security Type	Common Stock
Shares Involved	10,000
Price Per Share	$14.71 (approximate)
Total Value	$147,100
Shares Owned After	Not Disclosed
Ownership Type	Not Disclosed

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$147,100
% of Market Cap	0.0065%
Shares Transacted	10,000
% of Shares Outstanding	0.0066%
Post-Transaction Ownership	Not Disclosed
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $147,100 transaction is negligible against the company's $2.26 billion market capitalization.
• Transaction Significance: The sale represents a tiny fraction of both the market cap and total shares outstanding, indicating it is not a material event for the company or its stock.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is small and, more importantly, conducted under a Rule 10b5-1 plan established months prior. This indicates the sale is for personal financial management (e.g., diversification, liquidity) rather than a reaction to non-public information about the company's prospects.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is too small to have a noticeable effect on daily trading volume.
• Sentiment Indicator: Neutral. Pre-planned sales by insiders are routine and typically do not influence market sentiment.

Additional Context

Special Circumstances

• The filing explicitly states that the proposed sale is made in connection with a selling plan dated August 11, 2025, intended to comply with Rule 10b5-1(c). This automates the transaction and severs the direct link between the sale and the insider's immediate sentiment.